SINO BIOPHARM (01177) announced that its wholly-owned subsidiary, Hangzhou Hejiya Biopharmaceutical Co., Ltd., has completed the first patient enrollment in the United States for the Phase II clinical trial (KYLO-11-II-C01) of its self-developed innovative drug, KYLO-11 "LPA siRNA." The trial targets patients with atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein(a) (Lp(a)). Previously, the first patient enrollment in China for this clinical trial was completed in October 2025. KYLO-11 is an siRNA drug independently developed by Hejiya Biopharmaceutical that targets the LPA gene and has the potential to be best-in-class globally. Utilizing a proprietary siRNA delivery technology platform—the first of its kind in China to receive global patent authorization—and a world-first dual-conjugated siRNA delivery technology (MVIP delivery platform), KYLO-11 offers advantages such as efficient delivery, prevention of antisense strand degradation by exonucleases, enhanced in vivo stability, and reduced degradation of the antisense strand in plasma. These features enable an ultra-long-lasting effect, positioning the drug as a potential once-yearly siRNA treatment in the field of Lp(a)-targeted therapy.